Results 161 to 170 of about 30,994 (308)

Periodontal Disease and Salivary Gland Dysfunction in Neurofibromatosis Type 1: A Case–Control Study

open access: yesOral Diseases, EarlyView.
ABSTRACT Objectives Neurofibromatosis type 1 (NF1) presents with diverse systemic and oral manifestations. The aim of this study was to investigate the periodontal status and salivary alterations in NF1 individuals. Methods A total of 38 individuals with NF1 diagnostic criteria were compared with a control group paired by age and sex.
Eloá Borges Luna   +6 more
wiley   +1 more source

Lifestyle modification in atrial fibrillation: Mechanisms, phenotypes and ablation outcomes

open access: yesExperimental Physiology, EarlyView.
Abstract Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia and is associated with significant morbidity, mortality and healthcare utilization. Catheter ablation is increasingly used as a rhythm‐control intervention for patients with symptomatic paroxysmal and persistent AF, yet recurrence rates remain suboptimal.
Konstantinos Grigoriou   +11 more
wiley   +1 more source

Haemodynamic responses to head‐up tilt versus lower‐body negative pressure in type 1 diabetes

open access: yesExperimental Physiology, EarlyView.
Abstract Head‐up tilt (HUT) and lower‐body negative pressure (LBNP) both reduce central blood volume but differ in heart orientation and regional fluid shifts. Whether they evoke comparable cardiovascular regulation when matched for preload remains uncertain.
Victorien Faivre‐Rampant   +8 more
wiley   +1 more source

Deciphering pro‐arrhythmogenic mechanisms of EPAC in human atrial cardiomyocytes

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend This study aimed to investigate the effect of exchange proteins directly activated by cAMP (EPAC) on the regulation of human atrial cardiomyocyte electrophysiology and their potential involvement in the onset of atrial fibrillation (AF).
Arthur Boileve   +11 more
wiley   +1 more source

Sex‐specific metabolic responses to glucagon receptor agonism and modulation of the FGF21‐glucagon axis in female mice

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Therapies targeting the glucagon receptor are being explored for obesity treatment, yet most preclinical studies remain male biased. In this study, Merrild and Johansen et al. show that in diet‐induced obese wild‐type mice a long‐acting glucagon analogue (LA‐Gcg) elicits sexually dimorphic effects on weight loss, food intake ...
Christoffer Merrild   +3 more
wiley   +1 more source

Adaptations of glucagon‐like peptide‐1 receptor agonist‐induced weight loss, drivers of weight regain and future directions of therapeutics

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend During GLP‐1RA treatment reduced appetite and energy intake, delayed gastric emptying, decreased visceral fat mass and improved glycaemic control contribute to weight loss. After treatment cessation these benefits are partially or completely reversed, resulting in weight regain, accompanied by increased appetite and energy intake,
Camille E. M. Piguet   +2 more
wiley   +1 more source

Brukertilpasset gips

open access: yes, 2019
Denne tekniske rapporten tar for seg utvikling og konstruksjon av en løsning som er designet for å erstatte dagens gipsprosess ved håndleddsbrudd. Løsningen innebærer å 3D-skanne en hånd og 3D-printe en brukertilpasset gipsskinne, og baserer seg på en tidligere hovedoppgave fra 2017. Denne prosessen skulle automatiseres ved å bruke dagens 3D-teknologi,
Sjåstad, Denis   +2 more
openaire   +1 more source

Weight Loss‐Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide

open access: yesDiabetes/Metabolism Research and Reviews, Volume 42, Issue 6, September 2026.
ABSTRACT Aims This study examined changes in body composition and bone mineral density (BMD) over 12 months in people with obesity and type 1 diabetes (T1D) treated with a GLP‐1 receptor agonist alone (GLP‐1RA) or a dual glucose‐dependent insulinotropic polypeptide (GIP/GLP‐1RA).
Ebaa Al Ozairi   +5 more
wiley   +1 more source

GIP [PDF]

open access: yes, 2019
openaire   +1 more source

Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era

open access: yesEndocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
Tirzepatide and SGLT2 inhibitors act through distinct but complementary mechanisms in obesity‐related HFpEF: tirzepatide targets adiposity, inflammation, and insulin resistance, while SGLT2 inhibitors improve decongestion, myocardial energetics, and cardiac remodeling.
Zakariye Isak Mohamed   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy